PARP inhibitors--current status and the walk towards early breast cancer (Q37947887)

25 August 2017

PARP inhibitors--current status and the walk towards early breast cancer (English)

1 reference

25 August 2017

Jennifer Glendenning

1

1 reference

PubMed ID

22015278

25 August 2017

Andrew Tutt

series ordinal

2

1 reference

25 August 2017

1 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

20 Suppl 3

1 reference

25 August 2017

S12-9

1 reference

Hallmarks of Cancer: The Next Generation

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

The DNA damage response: ten years after

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

The concept of synthetic lethality in the context of anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Poly(ADP-ribose): novel functions for an old molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

The role of the BRCA1 tumor suppressor in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

BRCA2 is required for homology-directed repair of chromosomal breaks

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Triple-negative breast cancer--current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Resistance to therapy caused by intragenic deletion in BRCA2

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

PARP inhibition: PARP1 and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

BRCA1 dysfunction in sporadic basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Complex landscapes of somatic rearrangement in human breast cancer genomes

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970288-0

7 January 2021

10.1016/S0960-9776(11)70288-0

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22015278